CAR T-Cell Therapy Starts to Enter MCL Space
Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.
Brentjens Highlights BCMA, Next Steps With CAR T-Cell Therapy
Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.
Flinn Sheds Light on Advances in MCL and Other Lymphomas
Ian W. Flinn, MD, PhD, discusses the impact of CAR T-cell therapy on the field of lymphoma and highlighted emerging options for the treatment of patients with MCL.
Alternative Treatment Options Emerging for Relapsed Pediatric Patients With ALL
Susan R. Rheingold, MD, discusses the impact of CAR T-cell therapy on patients with ALL and options for patients who relapse on treatment.
Triplet Regimens, Maintenance Therapy New Standards for Multiple Myeloma
Alfred L. Garfall, MD, MS, discussed the treatment and management of patients with multiple myeloma, with a focus on maintenance therapy, CAR T-cell therapy, and the role of transplant.
Expert Discusses Approval of First CAR T-Cell Therapy
James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.
Axicabtagene Ciloleucel Emerges as Potential Standard for Some NHL Patients
Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.
Expert Discusses State of CAR T-Cell Therapy in ALL
Bajil J. Shah, MD, discusses the significant impact CAR T-cell therapy can have on the treatment landscape for patients with acute lymphoblastic leukemia.
Expert Discusses CAR T-Cell Advances in ALL
Stephan Grupp, MD, PhD, discusses the phase II ELIANA study results and the next steps with chimeric antigen receptor T-cell therapy in acute lymphoblastic leukemia.
Expert Discusses JCAR017 CAR T-Cell Therapy in Non-Hodgkin Lymphoma
Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.
2 Commerce Drive Cranbury, NJ 08512